PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget drug candidate against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD drug development[1].
PQM130 (0.5-1 mg/kg, i.p., daily for 10 days) treatment after the i.c.v. AβO injection reduces oxidative damage and neuroinflammation and induces cell survival and protein synthesis through the modulation of GSK3β and extracellular signal-regulated kinases (ERK1/2) [1]. Animal Model: Adult male C57Bl/6 mice (9 weeks old, 25-30 g body weight) [1].
[1]. Morroni F, et al. PQM130, a Novel Feruloyl-Donepezil Hybrid Compound, Effectively Ameliorates the Cognitive Impairments and Pathology in a Mouse Model of Alzheimer's Disease. Front Pharmacol. 2019 Jun 12;10:658.